Robert P. Ryan

viDA Therapeutics, Inc. operates as a biotechnology company. It offers discovery, development and commercialization of novel and targeted therapeutics for the treatment of inflammatory and age related diseases. The firm's discovery platform is based on novel research regarding a distinctly different and recently identified, extracellular role for granzymes in the destruction and inflammation of tissues. The company was founded by Alistair Duncan Jr. and David Granville in 2008 and is headquartered in Vancouver, Canada.

Innova Therapeutics, Inc. develops drug candidates for rare and orphan diseases. The private company is based in Palo Alto. Robert P. Ryan has been the CEO of the American company since 2016.

Aegle Therapeutics Corp. is a biotechnology company, which isolates extracellular vesicles including exosomes (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric connective tissue disorder. Its EV therapy has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. The company was founded by Evangelos V. Badiavas, and Robert F. Williamson III in 2013 and is headquartered in Miami, FL.

Renovion, Inc. develops therapy for chronic inflammatory airway diseases. It offers Arina-1, a nebulized therapy focused on chronic inflammatory airways diseases that is being evaluated as a twice daily nebulized therapy. The company was founded in 2013 and is headquartered in Chapel Hill, NC.

Part of UCB SA, UCB, Inc. provides financial services. The company is based in Smyrna, GA. The CEO of the company is Duane Barnes.

Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ.